Skip to main content
OpenTrials
Completed

NCT Number: NCT02786823

Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes

This study aims to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes. 80 selected subjects will be divided into 4 groups of 20 each.

* Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs.

The biochemical parameters will be evaluated before and after the intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

All India Institute of Medical Sciences, Bhubaneswar

Bhubaneswar, Odisha, 751019, India

About this study

This is a randomized, parallel group, open label study to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes.

80 selected subjects will be randomly assigned to 4 groups of 20 each as follows:

  • Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs;
  • Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs;
  • Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs;
  • Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs.

The subjects will also be advised to be on a normal routine diet, not to skip any meal and not to change their exercise pattern (if any) during the study period.The compliance of the intervention will be monitored by instructing the patients to return all unused tablets at the end of the 8 weeks period of study.

All the subjects will be asked to report after an overnight fasting of 12 hours on two occasions i.e. at the start of the study before allocation of group and 8 weeks after allocation. After measurement of body weight, height and blood pressure (by Mercury Sphygmomanometer), 5 milliliter of early morning fasting venous blood sample will be collected under aseptic measures on both the occasions. The samples collected will then be appropriately processed for the analysis of various biochemical parameters.

The results of all the parameters evaluated will be recorded in the subject's Data Collection Form.The data will be analyzed using Statistical Package for the Social Sciences (SPSS) version 21.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 Diabetic patients within age group 30-65 years, on stable dose of anti-diabetic with/without anti-hypertensive drugs will be included in this study

Exclusion criteria

  • Subjects on non-allopathic forms of treatment for diabetic control.
  • Subjects with Chronic Renal disease and Liver disease.
  • Subjects with malabsorption.
  • Subjects with Thyroid function abnormalities.
  • HbA1c levels more than 10 %
  • Smoking
  • Alcoholism
  • Pregnant subjects
  • Subjects with vitamin B12 deficiency
  • Subjects already on Folate or Vitamin B12 supplementation due to some other medical condition
  • The detailed drug history of the subjects will be taken prior to including them in the study. Antibiotics like Fluoroquinolones; anti-seizure drugs like phenytoin; Corticosteroids and Hormonal Contraceptives; Hypolipidemic drugs like statins are known to affect Glucose metabolism and subjects on these medications will not be included in the study.

Treatment and study plan

Folic Acid

Dietary Supplement

tab. Folic acid 5 mg

Vitamin B12

Dietary Supplement

tab. Vitamin B12 500 mcg

Oral hypoglycemic agents [Metformin +/- Sulfonylurea]

Drug

Patients receiving either of the following oral hypoglycemic agents

  • Sulfonylurea
  • Metformin
  • Metformin plus Sulfonylurea

Other names: Metformin, Sulfonylurea

Primary outcomes

  1. HbA1c

    Time frame: 8 weeks

Secondary outcomes

  1. Fasting plasma glucose

    Time frame: 8 weeks

  2. Fasting plasma insulin

    Time frame: 8 weeks

  3. Insulin Resistance

    Time frame: 8 weeks

    Using Homeostatic model assessment (HOMA2 calculator which uses fasting plasma glucose and plasma insulin values to calculate insulin resistance)

  4. Serum total cholesterol

    Time frame: 8 weeks

  5. Serum triacylglycerol

    Time frame: 8 weeks

  6. Serum Low-density lipoprotein (LDL)

    Time frame: 8 weeks

  7. Serum High-density lipoprotein (HDL)

    Time frame: 8 weeks

  8. Serum Very Low-density lipoprotein (VLDL)

    Time frame: 8 weeks

  9. Serum Homocysteine

    Time frame: 8 weeks

  10. Serum Adiponectin

    Time frame: 8 weeks

  11. Serum Tumor Necrosis Factor (TNF)

    Time frame: 8 weeks

  12. Serum Interleukin-6 (IL-6)

    Time frame: 8 weeks

  13. Serum C reactive protein (CRP)

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

All India Institute of Medical Sciences, Bhubaneswar

Other

Registry information

Official study title

Effect of Folic Acid and Vitamin B12 Supplementation on Biochemical Parameters in Subjects With Type-2 Diabetes

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Jun 1, 2016
Registry last updated
Sep 19, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.